A Randomized, Open-label, Multicenter, Phase 1b/2 Study of Eribulin Mesylate in Combination with PEGylated Recombinant Human Hyaluronidase (PEGPH20) versus Eribulin Mesylate Alone in Subjects with Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC) - Regional Cancer Care Associates LLC

Clinical Trials

A Randomized, Open-label, Multicenter, Phase 1b/2 Study of Eribulin Mesylate in Combination with PEGylated Recombinant Human Hyaluronidase (PEGPH20) versus Eribulin Mesylate Alone in Subjects with Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Type of Cancer
Breast Oncology
Locations
Bethesda
Cape May Courthouse
Cherry Hill
Sponsor
Eisai
Protocol Number
E7389-M000-219
Cancer Diagnosis
To Learn More Call
201-510-0910